EPIRUS Biopharmaceuticals, Inc. announced that it has signed a royalty-bearing, multi-product collaboration agreement with Livzon Mabpharm Inc. Under the terms of the agreement, EPIRUS and Livzon will work together to develop, manufacture, and commercialize up to five biosimilar products. The first collaboration product is EPIRUS' Remicade biosimilar BOW015 (infliximab), which was recently approved in India. Livzon will conduct any additional development work necessary for the approval of BOW015 in China and Taiwan.

Livzon will also serve as the preferred supplier of BOW015 in these territories, following a transfer of EPIRUS' SCALETM manufacturing platform. Livzon will be responsible for all commercialization activities in its territories.